Symbio

Headquartered in Port Jefferson, NY, Symbio is a client-focused global full-service Clinical Research Organization (CRO). We manage all CRO core services in-house and have our offices in the USA and Europe. We deliver excellent service and provide experienced qualified personnel to strategically manage all aspects of your clinical trials. In November of 2023, NY-headquartered Symbio, LLC and CA-headquartered Dow Development Laboratories, LLC merged with Münster (Germany)-based Proinnovera. This merger created one of the world’s largest specialized dermatology-focused clinical research organization. In September of 2024, after a successful integration process, the group was renamed from Symbio Proinnovera to Symbio. Symbio offers expertise in Proof-of-Concept, medical device and Phase 1 – Phase 4 clinical studies and has completed over 650+ clinical studies to date, both in the USA and in Europe. Developing and maintaining excellent relationships with experienced clinical research sites are vital to the success of any study and every CRO. As a direct result of our site relationships, Symbio trials receive the special attention they deserve. We take great pride in the strong relationships we have established over the years. These relationships have provided us the ability to streamline recruitment, creating shorter enrollment timelines with a lower number of sites.